DMN.F Diamyd Medical AB (publ)

Healthcare Biotechnology Frankfurt Exchange
0.0648 EUR
Close of Nov 12, 2026
0.0539 1.80
Market cap
EUR 9.81M
P/E
-
P/B
0.47x
ROE
-104.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Aug 2026.

Is DMN.F undervalued?

Graham number

The Graham number of Diamyd Medical AB (publ) cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Diamyd Medical AB (publ) fundamental analysis

No fundamental analysis for Diamyd Medical AB (publ) yet.

Diamyd Medical AB (publ) stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Diamyd Medical AB (publ)

Diamyd Medical AB (publ) develops precision medicine therapies for the treatment of autoimmune diabetes. It develops Diamyd, an antigen-specific immunotherapy, which is in phase III clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes in adults (LADA); and Remygen, an immunomodulation therapy, that is in phase I/II clinical trial for the treatment of with type 1 diabetes, type 2 diabetes, and LADA. The company was formerly known as Diamyd Therap…

Full company profile